NovoCure Ltd
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: February 27, 2025
| NovoCure Limited | |
| By: | /s/ Ashley Cordova |
| Ashley Cordova | |
| Chief Executive Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
| Date: | Signature | Title |
|---|---|---|
| February 27, 2025 | /s/ Ashley Cordova | Chief Executive Officer (Principal Executive Officer) |
| Ashley Cordova | ||
| February 27, 2025 | /s/ Christoph Brackmann | Chief Financial Officer (Principal Financial and Accounting Officer) |
| Christoph Brackmann | ||
| February 27, 2025 | /s/ William F. Doyle | Executive Chairman and Director |
| William F. Doyle | ||
| February 27, 2025 | /s/ Asaf Danziger | Director |
| Asaf Danziger | ||
| February 27, 2025 | /s/ Jeryl L. Hilleman | Director |
| Jeryl L. Hilleman | ||
| February 27, 2025 | /s/ David T. Hung | Director |
| David T. Hung | ||
| February 22, 2024 | /s/ Kinyip Gabriel Leung | Director |
| Kinyip Gabriel Leung | ||
| February 22, 2024 | /s/ Martin J. Madden | Director |
| Martin J. Madden | ||
| February 27, 2025 | /s/ Allyson Ocean | Director |
| Allyson Ocean | ||
| February 22, 2024 | /s/ Timothy J. Scannell | Director |
| Timothy J. Scannell | ||
| February 22, 2024 | /s/ Kristin Stafford | Director |
| Kristin Stafford | ||
| February 22, 2024 | /s/ William A. Vernon | Director |
| William A. Vernon |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.